Single cell & spatial multiomics

Maximize insights, maximize success in pharma

A graphic representing four distict phases of the pharma development pipeline

Boost confidence in every decision across your drug development pipeline with single cell and spatial context

Speak to an expert
Download brochure

Transforming drug development with single cell and spatial

Get high-resolution insights that will improve your odds of finding better targets, selecting the best leads, comprehensively profiling mechanisms of action (MOA), assessing safety and toxicity, identifying more actionable response and resistance biomarkers, and reducing clinical trial failures.

A graphic showing the different phases of a clinical trial
A graphic showing step one of the four steps in the pharma pipeline

Unlocking the right targets for tomorrow's therapies

Pain point

Challenges selecting the best targets

Traditional tools provide an incomplete understanding of disease biology, making it difficult to separate good targets from bad ones.

How single cell and spatial multiomics can help

Uncover hidden biology for better target selection

Identify and validate actionable targets with a deeper understanding of the cellular heterogeneity and context driving disease pathology.

quote

We're leveraging [10x Genomics technology] in target identification to better understand diseases and for finding new drug targets. We get this really amazing view into things with high resolution, which allows us to understand the differences between the cells of various different diseases we are interested in.

Sophia Wild, PhD

Principal Scientist at Novartis

Single cell and spatial applications in target ID and validation

A graphic representing CRISPR screening

Functional genomics

Identify and validate druggable targets with single cell CRISPR screening

A graphic showing human lungs

Disease pathology

Profile the heterogeneity and rare cell types implicated in disease progression and response

A graphic showing human stomach from which a sample is placed on a microscope slide

Biomarker discovery

Identify/validate biomarkers that predict desired disease response to therapeutic interventions

A graphic showing DNA coiled around ribosomes

Epigenetic discovery

Pinpoint the epigenetic modifications that drive disease progression

A graphic of a brain and circuitry representing artificial intelligence

AI-powered discovery

Combine multimodal data with AI to discover new targets and biomarkers

Featured publication

Featured publication

Spatial transcriptomic characterization of pathologic niches in IPF

Highlighted how disease-specific niches drive pathology, offering actionable insights for druggable targets.

Featured publication

Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation

Determined that targets with cell-type-specific expression identified by scRNA-seq were more likely to move into clinical development and pass Phase 1.

Other featured resources

A graphic showing step two of the four steps in the pharma pipeline

More mechanistic insights, more effective lead prioritization

Pain point

Struggle to refine selection of candidates

Inefficient hit screening tools fail to resolve therapeutic effects and mechanisms with the necessary level of detail.

How single cell and spatial multiomics can help

Reveal therapeutic mechanisms to prioritize the best leads

Assess the MOA of lead candidates at the cellular level on diverse cell populations and pathways.

A slide from a presentation by Goldstein LD, et al. Commun Biol. 2: 304 (2019).
quote

Our results demonstrate that scBCR-seq can be used for rapid discovery of large, diverse panels of high-affinity antigen-specific antibodies with natively paired heavy- and light-chains when combined with high-quality antigen-specific B-cell sorting.

Goldstein LD, et al. Commun Biol. 2: 304 (2019).

Quote and image used under CC BY 4.0

View publication

Single cell and spatial applications in candidate development

A graphic a zoomed in section showing the content of three wells of a 96-well plate.

Hit discovery and screening

Identify initial therapeutic candidates, including antibodies, that show potential activity against a desired disease target

A graphic showing 14 antibodies with 4 of them highlighted.

Hit-to-lead optimization

Refine the initial hits, including promising antibodies, to improve their properties, such as potency, selectivity, and pharmacokinetics

Featured publication

Featured publication

Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies

Resolved antigen-reactive B-cell lineages and reliably pinpointed high-affinity antibodies, accelerating candidate optimization and validation.

Featured publication

Pooled knockin targeting for genome engineering of cellular immunotherapies

Provided high-dimensional insights into T-cell states and transcriptional programs induced by knockin constructs, enabling precise functional validation and refinement of promising candidates.

Other featured resources

A graphic showing step two of the four steps in the pharma pipeline

Optimize IND readiness with deeper preclinical insights

Pain point

Gathering only limited insights into MOA, pharmacodynamics, pharmacokinetics, toxicity, and safety

Lack of robust molecular data leads to poor predictions about ADME/tox, efficacy, and safety of therapies.

How single cell and spatial multiomics can help

Obtain high-resolution preclinical profiles to support IND filings

Get cellular- and tissue-level MOA, efficacy, and safety data to select better drug–target combinations to advance to trials.

A slide from a presentation by Emilio Yangüez, PhD, from Roche.
quote

The preclinical team contacted us to do single cell RNA sequencing with the goal of understanding which of the cell types were responsible for generation of interferon response genes. We were able to find gene signatures associated with the treatment with a TLR7 agonist.

Emilio Yangüez, PhD

Senior Scientist, Roche

Single cell and spatial applications in preclinical development

A graphic of a cells interacting with receptors and antibodies

Mechanism of action studies

Assess the therapeutic MOA using preclinical models

A graphic of a skull and crossbones

Toxicity and safety

Monitor and evaluate the toxicity and safety of the drug using preclinical models

A graphic showing a human body with an excerpt of drug interaction in the digestive region and a graph showing concentration over time.

Pharmacokinetics/pharmacodynamics

Examine the biodistribution and impact of therapeutic compounds on cells and tissues

A graphic showing a chart of cells involved in immune response

Immunogenicity assessment

Evaluate the potential of drug candidates to elicit an immune response

A graphic of a bottle of pills.

Efficacy and response studies

Assess the efficacy and response of the drug in preclinical studies

Featured publication

Featured publication

TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

Demonstrated howTGFβ-blockade reshapes the tumor microenvironment to enhance immunotherapy efficacy, providing strong preclinical evidence for the effectiveness of this combination strategy.

Featured publication

Single-nuclei RNA sequencing assessment of the hepatic effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin

Uncovered cell-specific transcriptional responses and population shifts in the liver following TCDD treatment, which were critical for understanding the mechanisms of TCDD-induced toxicity.

Featured publication

Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies

Revealed a rare neural cell population that may explain the neurotoxicity observed in patients receiving CD19 CAR-T therapy as a result of unintended targeting.

Featured publication

Spatial single-cell transcriptomic analysis in breast cancer reveals potential biomarkers for PD1 blockade therapy

Highlighted how the spatial organization of cells and their interactions are often crucial for understanding therapeutic responses and provided evidence for using ligand–receptor activity as a predictive biomarker for therapy response.

Other featured resources

A graphic showing step four of the four steps in the pharma pipeline

Increase clinical trial success with high-resolution insights

Pain point

Imprecise understanding of the biology of therapeutic response and resistance puts trials at risk

Not fully understanding mechanisms dictating response and resistance increases the chance of clinical trial failures.

How single cell and spatial multiomics can help

Gain a more complete view of therapeutic response in patient populations

Better understand response and resistance, plus confirm MOA, efficacy, and safety/toxicity to mitigate late-stage failures.

A slide from a presentation by Tian J, et al. Nat Med. 29: (2023).
quote

In what we believe is one of the first clinical trials to incorporate systematic scRNAseq analysis of paired pre- and on-treatment tumor biopsies from all patients, we identified a potential mechanism underlying the cooperativity observed between BRAF/MAPK inhibition and immune response.

Tian J, et al. Nat Med. 29 (2023).

Quote and image used under CC BY 4.0

Read blog about this Phase 2 trial

Single cell and spatial applications in clinical trials

A graphic of a cells interacting with receptors and antibodies

Mechanism of action studies

Assess the therapeutic MOA in clinical trial samples

A graphic of a skull and crossbones

Toxicity and safety

Monitor and evaluate the toxicity and safety of the drug in clinical trial samples

A graphic showing a human body with an excerpt of drug interaction in the digestive region and a graph showing concentration over time.

Pharmacokinetics/pharmacodynamics

Examine the biodistribution and impact of therapeutic compounds on cells and tissues

A graphic showing a chart of cells involved in immune response

Immunogenicity assessment

Evaluate the potential of drug candidates to elicit an immune response

A graphic of a bottle of pills.

Efficacy and response studies

Assess the efficacy and response of the drug in clinical trial samples

Featured publication

Featured publication

Spatial biomarkers of response to neoadjuvant therapy in muscle-invasive bladder cancer: the DUTRENEO trial

Demonstrated a strong association between spatial biomarkers and treatment responses.

Featured publication

Peripheral T cell expansion predicts tumour infiltration and clinical response

Determined T-cell clones and dynamics correlated with positive response and showed power of peripheral biomarkers for monitoring.

Featured publication

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Characterized tumor microenvironment features that played a critical role in therapeutic success or resistance.

Featured publication

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Highlighted the diversity of cells within the TIME and pinpointed the major pathologic response differences seen between treatment regimens.

Featured publication

Randomized phase II trial of dendritic cell/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401

Revealed how vaccination impacted the immune repertoire post-vaccination and validated the efficacy of this treatment strategy.

Featured publication

Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer

Clarified the transcriptional mechanisms promoting treatment response and potentially alleviating tumor resistance to standard treatments.

Other featured resources

Tools tailored for every stage of drug development

Ready to get started? Learn more about our single cell and spatial offerings that can support your whole drug development pipeline from discovery to clinical trials, giving you the flexibility to choose the best tool for your specific needs.

Platform

Chromium Single Cell platform

Chromium Single Cell platform

See Chromium products
Visium Spatial platform

Visium Spatial platform

Xenium Spatial platform

Xenium Spatial platform

When to use

Comprehensive single cell data

Ideal for deep characterization of cell populations and states.

High-resolution spatial gene expression

Understand complex tissues, cellular neighborhoods, and cell to cell interactions. Integration with other spatial-omics, histology, and morphology. 

Why to use

Unbiased single cell discovery

High per-gene sensitivity

Unbiased spatial discovery

Targeted spatial exploration

High per-gene sensitivity

Analytes

Whole transcriptome gene expression

Protein

TCR, BCR

CRISPR

ATAC

Whole transcriptome gene expression

Targeted gene expression (up to 5,000 genes)

Resolution

Single cell

Transcripts assigned to 2-µm areas

Single cell

Data readout

NGS-based

NGS-based

Imaging-based

Sample compatibility

Cell and nuclei suspension,

Tissue (fresh, frozen, FFPE, PFA-fixed)

Flow-sorted cells

Fixed whole blood and PBMCs

Organoids

FFPE

Fresh frozen

Fixed frozen

Fresh frozen

FFPE

Access the power of single cell and spatial through Service Providers

Looking for flexibility or additional support? Our Service Provider Network offers a way to access 10x Genomics’ cutting-edge technologies without the need for an in-house setup.

Find a Service Provider
A molecular biology laboratory bench with a 10x Genomics Chromium X instrument and reagents